Innoviva (INVA) Total Liabilities (2009 - 2026)
Innoviva posted quarterly Total Liabilities of $200000.0 for Q1 2026, little changed year-on-year from $200000.0 in Q1 2025, and little changed on a QoQ basis from $200000.0 in Q4 2025.
Innoviva (INVA) has 18 years of Total Liabilities data on file, last reported at $200000.0 in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities changed 0.0% year-over-year to $200000.0; the trailing twelve-month figure through Mar 2026 stood at $200000.0 (changed 0.0% YoY), and the FY2025 full-year result was $200000.0, changed 0.0% from the prior year.
- Total Liabilities for Q1 2026 stood at $200000.0, roughly flat from $200000.0 in the prior quarter.
- Across five years, Total Liabilities topped out at $12.4 million in Q1 2022 and bottomed at $100000.0 in Q4 2023.
- The 5-year median for Total Liabilities is $600000.0 (2024), against an average of $1.8 million.
- Peak annual rise in Total Liabilities reached 700.0% in 2022, while the deepest fall reached 99.95% in 2022.
- A 5-year view of Total Liabilities shows it stood at $1.6 million in 2022, then tumbled by 93.75% to $100000.0 in 2023, then soared by 100.0% to $200000.0 in 2024, then changed by 0.0% to $200000.0 in 2025, then changed by 0.0% to $200000.0 in 2026.
- The last three Total Liabilities figures came in at $200000.0 (Q1 2026), $200000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 1.80 Mn |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 700,000.00 |
| Mar 31, 2023 | 4.10 Mn |
| Dec 31, 2022 | 1.60 Mn |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 6.40 Mn |
| Mar 31, 2022 | 12.43 Mn |
| Dec 31, 2021 | 200,000.00 |
| Sep 30, 2021 | 395.43 Mn |
| Jun 30, 2021 | 395.41 Mn |
| Mar 31, 2021 | 391.61 Mn |
| Dec 31, 2020 | 391.73 Mn |
| Sep 30, 2020 | 387.38 Mn |
| Jun 30, 2020 | 386.81 Mn |
| Mar 31, 2020 | 382.14 Mn |
| Dec 31, 2019 | 382.71 Mn |
| Sep 30, 2019 | 392.19 Mn |
| Jun 30, 2019 | 395.61 Mn |
| Mar 31, 2019 | 390.17 Mn |
| Dec 31, 2018 | 389.14 Mn |
| Sep 30, 2018 | 385.97 Mn |
| Jun 30, 2018 | 494.06 Mn |
| Mar 31, 2018 | 489.49 Mn |
| Dec 31, 2017 | 610.04 Mn |
| Sep 30, 2017 | 613.93 Mn |
| Jun 30, 2017 | 668.75 Mn |
| Mar 31, 2017 | 726.06 Mn |
| Dec 31, 2016 | 731.99 Mn |
| Sep 30, 2016 | 738.41 Mn |
| Jun 30, 2016 | 741.21 Mn |
| Mar 31, 2016 | 749.80 Mn |
| Dec 31, 2015 | 751.58 Mn |
| Sep 30, 2015 | 760.63 Mn |
| Jun 30, 2015 | 756.08 Mn |
| Mar 31, 2015 | 748.84 Mn |
| Dec 31, 2014 | 745.00 Mn |
| Sep 30, 2014 | 746.85 Mn |
| Jun 30, 2014 | 793.14 Mn |
| Mar 31, 2014 | 341.78 Mn |
| Dec 31, 2013 | 382.13 Mn |
| Sep 30, 2013 | 335.97 Mn |
| Jun 30, 2013 | 509.06 Mn |
| Mar 31, 2013 | 500.01 Mn |
| Dec 31, 2012 | 213.55 Mn |
| Sep 30, 2012 | 210.66 Mn |
| Jun 30, 2012 | 210.17 Mn |
| Mar 31, 2012 | 211.60 Mn |
| Dec 31, 2011 | 345.83 Mn |
| Sep 30, 2011 | 342.48 Mn |
| Jun 30, 2011 | 340.60 Mn |
| Dec 31, 2010 | 353.62 Mn |
| Dec 31, 2009 | 188.99 Mn |